PREDICTFTD

Accelerating the Validation of Predictive Liquid Biomarkers for Frontotemporal Dementia Diagnosis and Subclassification

We are proud to create a diagnostic tool for early FTD detection, enabling tailored care and treatment.



Mission

To advance early and accurate FTD diagnosis through innovative biomarkers and AI-driven tools, enabling personalized care and support.

Vision

To transform FTD diagnosis and care, enabling early intervention and personalized treatments for better patient outcomes.

Why PREDICTFTD?

Debilitating effect on patients and their caregivers

Robust Two-Stage Validation Approach

Phase I validates biomarkers and algorithms on a cohort of genetic and autopsied cases and phase II assesses biomarker value for diagnosis of all FTD patients and at-risk pre-symptomatic mutation carriers.

11 Geographically Diverse Cohorts

We combine 11 geographically diverse cohorts of sporadic and familial FTD with retrospective and prospective longitudinal liquid biopsy samples and extensive clinical and behavioural data.

Multimodal Clinical & Liquid Biomarker Data

We are the first to use multimodal clinical and liquid biomarker data to train an AI-algorithm as a diagnostic tool.

About FTD

Frontotemporal dementia (FTD) has a debilitating effect on patients and their caregivers and leads to substantial economic costs.

15-30%

Familial FTD

15-30% of patients have familial FTD caused by known pathogenetic mutations.

70-85%

Sporadic FTD

For the other 70-85% of patients, termed sporadic FTD, diagnosis is slow (~3.6 years) with frequent misdiagnosis due to clinical, genetic and molecular heterogeneity.

Funded by the European Union

Funded by the European Union (PREDICTFTD, 101156175). Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.